Two Sigma Investments LP Purchases 151,001 Shares of Altimmune, Inc. (NASDAQ:ALT)

Two Sigma Investments LP lifted its holdings in Altimmune, Inc. (NASDAQ:ALT - Free Report) by 33.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 605,303 shares of the company's stock after purchasing an additional 151,001 shares during the quarter. Two Sigma Investments LP owned 0.85% of Altimmune worth $4,364,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. SBI Securities Co. Ltd. purchased a new position in Altimmune during the fourth quarter worth $45,000. Virtus ETF Advisers LLC purchased a new position in Altimmune during the fourth quarter worth $60,000. Cullen Frost Bankers Inc. purchased a new position in Altimmune during the fourth quarter worth $72,000. KLP Kapitalforvaltning AS purchased a new position in Altimmune during the fourth quarter worth $81,000. Finally, Raymond James Financial Inc. purchased a new position in Altimmune during the fourth quarter worth $88,000. 78.05% of the stock is owned by hedge funds and other institutional investors.

Altimmune Price Performance

Shares of NASDAQ:ALT traded down $0.13 on Monday, hitting $5.30. 2,499,124 shares of the company's stock were exchanged, compared to its average volume of 2,820,878. Altimmune, Inc. has a 12 month low of $3.55 and a 12 month high of $11.16. The stock has a market capitalization of $429.87 million, a price-to-earnings ratio of -3.42 and a beta of 1.13. The business's 50 day simple moving average is $5.08 and its two-hundred day simple moving average is $6.39.

Altimmune (NASDAQ:ALT - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.09. The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. During the same period in the previous year, the company posted ($0.34) earnings per share. Equities analysts forecast that Altimmune, Inc. will post -1.35 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on ALT shares. HC Wainwright reiterated a "buy" rating and set a $12.00 target price on shares of Altimmune in a research report on Thursday, April 3rd. Wall Street Zen upgraded Altimmune from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Finally, William Blair reiterated a "market perform" rating on shares of Altimmune in a research report on Friday, March 14th. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $20.20.

Insider Activity at Altimmune

In other news, CFO Gregory L. Weaver acquired 10,000 shares of the firm's stock in a transaction that occurred on Thursday, March 13th. The stock was purchased at an average cost of $5.20 per share, for a total transaction of $52,000.00. Following the completion of the acquisition, the chief financial officer now directly owns 10,000 shares of the company's stock, valued at $52,000. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 4.10% of the stock is currently owned by corporate insiders.

Altimmune Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.